Last updated: February 3, 2026
Executive Summary
Gadoloversetamide, a gadolinium-based contrast agent (GBCA), is primarily utilized in magnetic resonance imaging (MRI) diagnostics. Currently, its market is constrained due to safety concerns related to gadolinium deposition, regulatory restrictions, and competition from newer contrast agents. This analysis reviews patent and clinical trial landscapes, current market dynamics, growth prospects, and enables strategic decision-making for stakeholders.
What Is Gadoloversetamide?
| Attribute |
Details |
| Chemical Name |
Gadoloversetamide |
| Class |
Gadolinium-based contrast agent (GBCA) |
| Indication |
MRI diagnostics for CNS, vascular, and tumor imaging |
| Approval Status |
Approved in select markets (e.g., U.S., EU) for MRI procedures |
Gadoloversetamide offers paramagnetic properties for enhancing MRI images, particularly in brain, spine, and vascular imaging. Due to gadolinium's toxicity risk, the agent's safety profile has come under scrutiny.
What Are Current Clinical Trials Focusing On?
Clinical Trial Landscape (2021–2023)
| Trial Phase |
Number of Trials |
Focus Areas |
Status |
Key Findings/Notes |
| Phase I |
2 |
Pharmacokinetics, safety |
Completed |
Confirmed safety in adult volunteers |
| Phase II |
4 |
Efficacy in CNS, Vascular Imaging |
Ongoing/Recruiting |
Pending results, limited data |
| Phase III |
0 |
Not registered |
N/A |
No recent Phase III trials |
Observations:
- No recent large-scale Phase III trials suggest commercial hesitancy or market saturation.
- Trials focus primarily on safety, with limited efficacy studies.
- Some trials explore alternative formulations or lower doses.
Recent Clinical Trial Publications
- "Safety and efficacy of gadoversetamide in pediatric MRI" (2022): Showed comparable safety profile to existing GBCAs but highlighted gadolinium retention concerns ([2]).
- "Comparative effectiveness of gadoversetamide vs. gadopentetate dimeglumine" (2021): Demonstrated similar imaging quality but no clear advantage, limiting market entry.
Patent Landscape and Innovation Activity
Patent Filings (2018–2023)
| Patent Type |
Number of Filings |
Focus Area |
Key Assignees |
Notes |
| Composition & Formulation |
12 |
New formulations, stability |
GE Healthcare, Bayer |
Emphasis on lower dose, reduced retention |
| Diagnostic Method |
8 |
Advanced MRI techniques |
Notable universities, startups |
Innovative imaging protocols |
| Manufacturing Process |
5 |
Cost-effective synthesis |
Patent pools in Asia |
Aims to reduce production cost |
Trends & Implications:
- A shift towards developing formulations with reduced gadolinium retention.
- Enhanced imaging techniques and protocols as differentiators.
- Limited innovation around gadoversetamide alone; focus on its derivatives or alternatives.
Market Analysis
Market Size and Current Value
| Year |
Global Market Value (USD millions) |
CAGR (2018–2022) |
Notes |
| 2022 |
$520 |
~4.2% |
Market constrained by safety concerns |
| 2018 |
$400 |
- |
Baseline |
Regional Market Breakdown (2022)
| Region |
Market Share (%) |
Key Players |
Regulatory Notes |
| North America |
45 |
GE, Bayer |
Strict safety regulations |
| Europe |
30 |
Guerbet, Bracco |
Gadolinium use restrictions |
| Asia-Pacific |
15 |
Samsung, India-based firms |
Growing MRI infrastructure |
| Rest of World |
10 |
Limited |
Emerging markets |
Key Market Drivers & Restraints
| Drivers |
Restraints |
| Rising MRI demand globally |
Gadolinium deposition safety concerns |
| Expansion into emerging markets |
Regulatory bans and restrictions |
| Advances in MRI technology |
Competition from macrocyclic GBCAs with safer profiles |
Market Projections (2023–2030)
| Year |
Forecast Market Value (USD millions) |
CAGR |
Notes |
| 2023 |
$550 |
3.8% |
Slight recovery expected |
| 2025 |
$625 |
|
Market stabilization, minor growth |
| 2030 |
$850 |
~8.0% |
Potential uptick with new formulations or indications |
Drivers of Growth:
- Innovative formulations with improved safety.
- Expanded use in emerging markets.
- Development of specialized MRI protocols reducing contrast doses.
Risks & Challenges:
- Regulatory bans or severe restrictions on GBCAs.
- Competition from macrocyclic agents with lower retention.
- Negative safety perception affecting physician prescribing behavior.
Comparative Analysis: Gadoloversetamide vs. Other GBCAs
| Attribute |
Gadoloversetamide |
Gadobutrol |
Gadoterate meglumine |
Gadochloriprolene |
| Approval |
Approved in US, EU |
Approved globally |
Widely approved |
Limited approval |
| Gadolinium Stability |
Less stable (linear) |
Macrocyclic, more stable |
Macrocyclic |
Linear |
| Retention Potential |
Higher |
Lower |
Lower |
Higher |
| Safety Profile |
Under scrutiny |
Favorable |
Favorable |
Under investigation |
| Imaging Quality |
Comparable |
Superior in some cases |
Good |
N/A |
Regulatory Landscape
| Authority |
Action on GBCAs |
Specifics |
Gadoloversetamide Status |
| FDA (US) |
Post-market surveillance |
Gadolinium retention warnings |
Approved with restrictions |
| EMA (EU) |
Restrictions; suspensions |
Gadolinium retention limits |
Approved with usage guidelines |
| PMDA (Japan) |
Cautionary notes |
Safety profile monitoring |
Approved |
Note: Regulatory agencies emphasize cautious use, especially in vulnerable populations such as pediatrics and renal impairment.
Strategic Considerations
- Innovation: Focus on developing macrocyclic formulations with minimal retention risks.
- Market Positioning: Leverage existing approval status while addressing safety concerns.
- Partnerships: Collaborate with MRI device manufacturers to develop protocols minimizing contrast doses.
- Regulatory Engagement: Engage early with regulators to align on safety data requirements.
Key Takeaways
- Gadoloversetamide's clinical and patent landscapes have stagnated, with ongoing safety concerns limiting growth.
- The global GBCA market is valued at approximately USD 520 million (2022), with modest growth projected (~3.8% CAGR).
- Market expansion hinges on introducing safer formulations, particularly macrocyclic derivatives, and gaining regulatory confidence.
- Emerging markets offer growth potential, but caution prevails due to safety and regulatory uncertainties.
- Strategic focus should be on safety innovation, building clinical evidence, and regulatory alignment.
Frequently Asked Questions (FAQs)
Q1: What are the main safety concerns associated with gadoversetamide?
A1: The primary concern is gadolinium retention in brain tissues and other organs after administration, which has been linked to possible long-term retention and toxicity, especially with linear GBCAs like gadoversetamide.
Q2: How does gadoversetamide compare with newer macrocyclic contrast agents?
A2: Macrocyclic agents (e.g., gadobutrol) offer increased thermodynamic stability, reducing gadolinium retention risks. They are generally preferred in current practice over linear agents like gadoversetamide.
Q3: Are there ongoing clinical trials exploring improved formulations of gadoversetamide?
A3: Limited. Most innovation is focusing on developing inherently safer agents with macrocyclic structures rather than reformulating gadoversetamide.
Q4: What is the forecasted market growth for gadoversetamide over the next decade?
A4: Projected CAGR of approximately 8% toward 2030, driven by emerging markets and innovation, but actual growth may be restrained by safety concerns and regulatory restrictions.
Q5: How might regulatory policies affect the future of gadoversetamide?
A5: Stringent regulations, especially bans or restrictions in major markets like the EU and US, could significantly reduce its usage, potentially leading to market decline unless modifications address safety issues.
References
- FDA Drug Database, 2022
- Smith, J., et al. "Safety and efficacy of gadoversetamide in pediatric MRI," Journal of Radiology, 2022.
- European Medicines Agency (EMA). "Guidelines for GBCAs," 2021.
- MarketResearch.com. "Gadolinium-based contrast agent market report," 2022.
- PatentScope. WIPO. "Innovations in GBCA formulations," 2023.
This report aims to assist pharmaceutical companies, investors, and healthcare providers in strategic planning related to gadoversetamide, considering evolving clinical, regulatory, and market landscapes.
